Buspar Dividose and Lapatinib Ditosylate
Determining the interaction of Buspar Dividose and Lapatinib Ditosylate and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Lapatinib may increase the blood levels and effects of busPIRone. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Contact your doctor if you experience increased side effects or your condition changes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration with lapatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-glycoprotein (P-gp) efflux transporter. The mechanism is decreased clearance via these routes due to inhibition by lapatinib. In cancer patients treated with lapatinib and paclitaxel, a CYP450 2C8 and P-gp substrate, 24-hour systemic exposure (AUC) of paclitaxel was increased by 23%. This increase may have been underestimated from the in vivo evaluation due to study design limitations. Lapatinib also increased the 24-hour AUC of midazolam, a CYP450 3A4 probe substrate, by 45% when midazolam was administered orally and 22% when administered intravenously. Likewise, lapatinib increased the AUC of single-dose digoxin, a P-gp probe substrate, by approximately 2.8-fold.
MANAGEMENT: Caution is advised if lapatinib must be used concurrently with medications that are substrates of the CYP450 2C8 isoenzyme, CYP450 3A4 isoenzyme, and/or P-gp efflux transporter, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever lapatinib is added to or withdrawn from therapy.
- "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.
Generic Name: buspirone
Brand name: Buspar, Buspar Dividose, Vanspar, Buspirex, Bustab, LinBuspirone
Synonyms: BuSpar
Generic Name: lapatinib
Brand name: Tykerb
Synonyms: Lapatinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Buspar Dividose-Lariam
- Buspar Dividose-Larin 1.5/30
- Buspar Dividose-Larin 1/20
- Buspar Dividose-Larin 24 Fe
- Buspar Dividose-Larin Fe 1.5/30
- Buspar Dividose-Larin Fe 1/20
- Lapatinib Ditosylate-Buspirone
- Lapatinib Ditosylate-Buspirone Hydrochloride
- Lapatinib Ditosylate-Busulfan
- Lapatinib Ditosylate-Busulfan Concentrate Injection
- Lapatinib Ditosylate-Busulfan Injection
- Lapatinib Ditosylate-Busulfan Intravenous